Search
Hypertension Paid Clinical Trials in Maryland
A listing of 26 Hypertension clinical trials in Maryland actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 26
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Dementia
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Alzheimer's Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
The Redwood Study is currently enrolling adults 18 to 75 years of age with Alpha-1
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Recruiting
Background:
- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH.
Objectives:
- To study the natur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Disease, Pulmonary Hypertension
Study of Intravenous ZMA001 in Healthy Subjects
Recruiting
Background:
A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people.
Objective:
To test a dru... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
11/28/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Arterial Hypertension PAH
Diabetes and Heart Disease Risk in Blacks
Recruiting
It is unknown if obesity contributes to the development of heart disease in African American men and women.
This study was created to determine whether there is a relationship between sex and body size and the incidence of heart disease in African American men and women. Researchers will attempt to associate obesity with the presence of heart disease risk factors. Risk factors that will be studied include; total body fat, body fat distribution, fat content of the blood (triglyceride concentrati... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/23/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Recruiting
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Johns Hopkins Hospital ( Site 1036), Baltimore, Maryland
Conditions: Pulmonary Arterial Hypertension
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Recruiting
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
11/23/2023
Locations: Research Site, Baltimore, Maryland
Conditions: Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
Recruiting
This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).
The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo in a base period of 12 weeks, followed by comparison of three different doses of MK-5475 during an optional 24 month extension period. The treatment dose with the best efficacy and safety profile in the phase 2 cohort base period will be selecte... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/23/2023
Locations: University of Maryland ( Site 0032), Baltimore, Maryland
Conditions: Pulmonary Arterial Hypertension, Hypertension, Pulmonary
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Johns Hopkins Pulmonary and Critical Care Medicine ( Site 1036), Baltimore, Maryland
Conditions: PAH, Pulmonary Arterial Hypertension
Spironolactone for Pulmonary Arterial Hypertension
Recruiting
Background:
- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high. Lung blood vessel function can be harmed by progressive injuries, such as inflammation, leading to worsening of the disease. A drug called spironolactone has been known to improve blood vessel function and reduce inflammation. Some people with PAH take spironolactone to help treat fluid retention.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/18/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Arterial Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2023
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
Recruiting
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study participants will be patients with rHTN, all study treatments will be given on top of maximally tolerated background antihypertensive therapy recommended by international guidelines for treatment of HTN (i.e., a thiazide or a th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: Novartis Investigative Site, Fort Washington, Maryland +1 locations
Conditions: Resistant Hypertension
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
All
Ages:
Between 3 months and 18 years
Trial Updated:
10/27/2023
Locations: Johns Hopkins Medical Institutions, Baltimore, Maryland
Conditions: Pediatric Pulmonary Hypertension
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires
Recruiting
Background:
A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers. Magnetic resonance imaging (MRI) fluoroscopy shows continuous pictures of the heart chambers that doctors can watch while they work. Researchers want to test this procedure with catheterization tools routinely used in x-ray catheterization called guidewires. Guidewires will help move the heart catheter through the different heart chambers.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
1 - 12 of 26